Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
about
Clinical utilities and biological characteristics of melanoma sentinel lymph nodesReflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune ResponsePathways and therapeutic targets in melanomaAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClinical and biological determinants of melanoma progression: Should all be considered for clinical management?Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.Melanoma: tumor microenvironment and new treatments.Emerging immunologic biomarkers: setting the (TNM-immune) stage.Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Inherited variation at MC1R and histological characteristics of primary melanoma.Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma GroupDecreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.Revisiting determinants of prognosis in cutaneous melanoma.Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study.Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastasesA phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts.Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based studyGenetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma.PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.Systematic evaluation of immune regulation and modulationIntralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies.The immune response in cancer: from immunology to pathology to immunotherapy.Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation.Predictive biomarkers for checkpoint inhibitor-based immunotherapy.Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanomaAssociations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanomaAssessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaBeyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
P2860
Q26747723-83B97EC1-C7B9-4CF5-A2E1-2D8390537E5AQ26799073-1C2DE2E6-1D75-4A85-ADED-ED7E3A664AABQ26865736-9DC971D2-4D54-46D4-BA03-45EE935A7A93Q29617774-86CDCDBE-81D7-4574-87CE-BDEF3E55D808Q30252150-2338DF6B-277F-43DC-A92F-26E4772F25A6Q30366026-E5D3F766-B2B9-45EC-82D9-D35261C702F8Q33675676-3A2D2267-CBDA-4C54-B402-913D5E992475Q33677916-16BAA1DF-1761-4EF1-A8A8-CDC23D1BBA2FQ35543740-A31363DD-165A-4CA8-BDAE-FE23A362264FQ35581399-80329F00-0209-4C4E-AE0C-78D4037A585BQ35801085-3C58E688-E148-472F-91D1-F4A936E3F854Q35918156-FCFDA249-032C-4B04-B8BD-A7A22CCFB4C4Q36019013-D65B390F-7B9F-42CB-AF18-4D67924600D2Q36338825-642F6267-92BC-45A8-8FD3-C09605E67A01Q36468811-5C096A2C-C9F6-428E-B760-6D0C9F9BA3BBQ36562180-2CA66667-1260-4CC2-82FB-49C4549899DCQ36562370-D4A1F7DE-770E-46CE-8840-C1199E509305Q36916445-94AD0A52-3D50-46A8-9F64-E559731BFF43Q37350143-88278C5C-6D1D-4CF4-A283-4BDF3BA1AE63Q37430032-C3DDF9F4-5B1B-4F09-B47B-12123471427AQ37514024-396D10DF-F04D-4678-A62B-96B5296B7421Q37630808-AC60B767-3419-4986-A1FD-5122C741C6A7Q37713498-7BE577CB-D9F2-4D58-BD98-21EEB7079C1FQ37725792-CDC5BE25-925B-482D-9296-6A1636C60AE3Q38217028-183F2C0E-EC55-4DE1-A4F3-8D9CBB01AA0EQ38226097-4A5030A4-BA75-472D-960C-F56E47DC234CQ38528448-8CC5E152-4E67-4DBA-9AB4-53EC1C189F06Q38584887-DA00C765-50BC-42EC-927C-0EC3886DE443Q38786289-32AC4D23-7D4D-465C-AC9F-1E9DEF2C3C07Q38800548-4018602E-3152-4575-B83B-132D426EB372Q38856722-34813D5B-39D2-4F7D-A274-2B971F691156Q39532055-02CFCBAA-2CC1-45D4-B4E8-C813307F6DACQ39832874-F2BB28D3-05A0-4203-A700-153F582CDB69Q40069925-2A878BBD-B2E0-4F6C-A526-EEF1EDDE9376Q40732246-06E8ADB2-B062-4B39-BA8E-29DDF762510AQ40759062-845969B5-01E9-4F1B-8172-E0B47576706DQ41431266-4BB69620-985D-446F-91AD-07E8BEC4016AQ41558364-3AD25BF1-B1C1-4D7B-AA38-D6B4F1870519Q46540302-2FCD6D7D-EFE7-477F-A8F6-3B0F16965D41Q47101079-E8F0FA54-12C7-46AA-9D4A-EBA1C96E4642
P2860
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@en
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@nl
type
label
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@en
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@nl
prefLabel
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@en
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@nl
P2093
P2860
P50
P356
P1476
Tumor-infiltrating lymphocyte ...... nvironment and melanoma study.
@en
P2093
Alison Venn
Anne Kricker
Colin B Begg
David W Ollila
Homer Wilcox
Honglin Hao
Klaus J Busam
Nancy E Thomas
P2860
P304
P356
10.1200/JCO.2013.51.3002
P407
P577
2013-10-14T00:00:00Z